Sales Enablement
Week ending August 19, 2026
1. What’s coming up in conversations this week
- Substitution and biosimilars: People are asking, “Can Keytruda be substituted?” AI answers repeatedly say substitution may depend on the prescription, payer, local policy, and product availability. Reps should expect questions about whether Keytruda has a generic or interchangeable biosimilar.
- Keytruda vs. Opdivo: The recurring question is how two PD-1 inhibitors differ in indications, biomarkers, line of therapy, dosing, combinations, and practical fit—not simply which one is “better.”
- “More effective” claims: Patients and prescribers may ask whether claims that Keytruda is more effective than Opdivo come from head-to-head trials or marketing. AI responses frequently caution that evidence is setting- and endpoint-specific.
- Keytruda vs. Tecentriq: AI commonly frames the distinction as PD-1 (Keytruda) versus PD-L1 (Tecentriq), with treatment choice depending on cancer type, stage, biomarkers, indication, and regimen.
- Practical prescribing questions: AI users are seeking labeled details on resected melanoma dosing, IV administration, AST/ALT elevations, warfarin, and eligibility concerns such as transplant history or autoimmune disease.
2. Competitive talking points
Opdivo (nivolumab) is the main comparison. AI describes both products as PD-1 inhibitors but emphasizes differing approved indications, biomarker requirements, treatment settings, combinations, and schedules. If a prescriber says Keytruda is “more effective,” “stronger,” “superior,” or “leading,” recognize that this language is circulating in AI answers—but it is not company-verified messaging. Bring the discussion back to the specific disease setting, endpoint, population, and approved evidence; use approved materials.
Tecentriq (atezolizumab) is framed around the PD-1-versus-PD-L1 distinction and differing indication and biomarker contexts. Keep the comparison indication-specific rather than treating mechanism alone as a treatment-choice conclusion.
3. Questions and objections to be ready for
- “Can the pharmacy substitute something else for Keytruda?” Six of six answers raised biosimilar, payer, or local-policy considerations; be ready to distinguish substitution from a therapeutic alternative and defer to applicable rules and the prescriber.
- “Is there a generic or biosimilar, and how does it compare with Opdivo?” Six responses addressed this, with availability and interchangeability varying by market—verify current local information.
- “What are the labeled AST/ALT actions and thresholds?” Six responses discussed hold-versus-discontinue decisions, but this is label-sensitive; direct the prescriber to current prescribing information and medical support.
- “What should I know about Keytruda with warfarin?” Six responses generally said no labeled CYP/P-gp interaction is expected, but one answer added a monitoring concern. Be ready to acknowledge the distinction between no classic interaction and patient-specific clinical monitoring.
4. What’s changed since last week
There is no prior-week comparison. Treat this as a baseline week, not evidence of a new or growing trend. Competitive comparisons and practical prescribing questions are priorities because each generated six responses.
5. Recommended actions
- Add a call-prep note on biosimilar/substitution questions, including “verify local label and policy.”
- Refresh the Opdivo comparison section with indication-specific, approved evidence and a reminder not to repeat AI superiority language.
- Give reps a current-reference prompt for melanoma dosing, administration, liver-test management, and eligibility.
- Flag the three inconsistency areas—administration, warfarin, and eligibility—for Medical/label review so reps have one consistent escalation path.
- No trend-based reprioritization yet; collect another week before calling any theme “growing.”